ANZSNM and AANMS made a joint submission to the House of Representatives Standing Committee on Health, Aged Care and Sport Inquiry into the approval processes for new drugs and novel medical technologies in Australia.
The inquiry has a focus on the treatment of rare diseases and conditions where there is high and unmet clinical need. It considers s Australia continuing to be well-positioned to access new drugs and novel medical technologies in a timely manner and respond to emerging global trends.
The joint submission noted Australia has an opportunity to develop a new industry of national significance and has the foundations for a very strong competitive advantage compared to other countries in the development of novel radiopharmaceuticals and theranostics.
This could become a significant national industry generating economic returns, employment and expertise. It would also give Australian patients early access to the latest treatments in trials and novel therapies.
The submission also recommended consideration should be given to a new “class” of “drug” that is a “radiopharmaceutical” with requirements that recognise the special nature of a radiopharmaceutical.
The submission is available to be viewed here AANMS ANZSNM submission to HOR inquiry into new drugs & novel technologies FINAL or on the Committee website https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Newdrugs